Mesenchymal stromal cells for sepsis and septic shock: Lessons for treatment of COVID-19.

Date publication

août 2020

Journal

Stem cells translational medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BENSOUSSAN Danièle

Tous les auteurs :
Laroye C, Gibot S, Huselstein C, Bensoussan D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32808462

Résumé

Sepsis is defined as life-threatening organ dysfunction caused by a deregulated immune host response to infection. The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has highlighted this multifactorial and complex syndrome. The absence of specific treatment neither against SARS-CoV-2 nor against acute respiratory distress syndrome (ARDS), the most serious stage of this infection, has emphasized the need to find alternative treatments. Several therapeutics are currently tested and among them, mesenchymal stromal cells. These cells, already used in preclinical models of ARDS, sepsis, and septic shock and also in few clinical trials appear well-tolerated, promising, but many questions remain unanswered.

Mots clés

COVID-19, Wharton's Jelly, acute respiratory distress syndrome, mesenchymal stromal/stem cells, sepsis

Référence

Stem Cells Transl Med. 2020 Aug 18;: